Laura, a Synthetic Chemist by training, brings over 19 years of drug discovery experience in covalent, targeted protein degradation and antibody drug conjugate modalities. Most recently, VP of Chemistry at Dunad Therapeutics developing covalent SNAr chemistry for expanded protein targeting. Previously at Bristol Myers Squibb and Celgene, she progressed small molecule and targeted protein degradation therapeutics for Immunology and Immuno-oncology. Earlier, she led chemistry teams at Avila Therapeutics accelerating covalent inhibitors targeting oncogenic drivers and resistance mutations in oncology.